Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 19/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 19/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 19/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 19/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 19/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 19/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786518 | 0.85 | GRIN2D (0.79) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Licostinel SCHEMBL464947 | 0.84 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Licostinel SCHEMBL30546249 | 0.84 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7471983 | 0.84 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7786601 | 0.83 | GRIN2D (0.74) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7473960 | 0.82 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2639506 | 0.81 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7473832 | 0.81 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7467072 | 0.81 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7784711 | 0.81 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | claimed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | claimed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | claimed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | claimed |
| EP-0783495-B1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LTD (GB) | 2002-02-27 | — | — | EP | disclosed |
| EP-0885212-B1 | QUINOXALINEDIONES | PFIZER RES AND BR DEV COMPANY (IE) | 2001-11-14 | — | — | EP | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0732942-A4 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | COCENSYS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5863917-A | ANXIOLYTIC AGENT, ANTICONVULSANTS, ANALGESICS AND NEUROPROTECTIVES. | PFIZER, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0885212-A1 | QUINOXALINEDIONES | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-12-23 | — | — | EP | disclosed |
| US-5852016-A | Quinoxaline derivatives useful in therapy | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998005337-A1 | USE OF GABA AND NMDA RECEPTOR LIGANDS FOR THE TREATMENT OF MIGRAINE HEADACHE | COCENSYS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997032873-A1 | QUINOXALINEDIONES | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-12 | — | — | WO | disclosed |
| EP-0792874-A1 | Quinoxaline derivatives useful in therapy | Pfizer Limited (GB) | 1997-09-03 | — | — | EP | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |